---
# System prepended metadata

title: Untitled

---

 Global Cancer Diagnostics Market

![](https://i.imgur.com/lLDiem5.jpg)

 


Global Cancer Diagnostics Market Insights
Global cancer diagnostics market was valued at USD 128.30 billion in 2021, and it is expected to reach a value of USD 219.89 billion by 2028, at a CAGR of more than 8% over the forecast period (2022–2028).
Globally, more than 10 million people die of various types of cancers. Cancer is a major cause of death worldwide, and it's becoming more common. According to the World Health Organization, cancer will kill more people in 2030 than any other disease. However, 50% disease burden can be reduced by 2050 if early cancer diagnosis is performed. There are many different types of cancer, and each one has its own risks and symptoms. Some cancers are more common in some groups of people than others, and some are more deadly.

Know more about : https://skyquestt.com/report/cancer-diagnostics-market 

Global Cancer Diagnostics Market Segmental Analysis
Global cancer diagnostics market is segmented by test, technology, application, end user and region. Based on the test, the market is segmented into instrument-based tests, laboratory tests, and liquid biopsies. Based on the application, the global cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach, liver, esophagus, thyroid, pancreatic cancer, leukemia, and others. Based on the technology, the market is bifurcated into platform-based and instrument-based. By test, the market is segmented into Hospitals, Diagnostic Laboratories, Others. Based on Region, it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Top Player's Company Profiles
•	GE Healthcare (US)
•	Abbott Laboratories (US)
•	Hologic Inc. (US)
•	Agilent Technologies Inc. (US)
•	Roche Diagnostics (Switzerland)
•	FUJIFILM Corporation (Japan)
•	Danaher Corporation (US)
•	DiaSorin S.P.A. (Italy)
•	Myriad Genetics Inc. (US)
•	Siemens Healthineers AG (Germany)
•	BD (US)
•	bioMérieux SA (France)

Get free sample pdf report copy at : https://skyquestt.com/sample-request/cancer-diagnostics-market 

Recent Developments
•	In June 2022, Karkinos Healthcare, one of the key players in the global cancer diagnostics market, introduced "introduced Advanced Center for Cancer Diagnostics and Research." The center would act as a central lab for the company's global oncology network, analyzing specimens at the molecular and genomic level to aid in personalized targeted therapy, predicting possible treatment response, and evaluating response via liquid biopsy.
•	In May 2022, Illumina unveiled a new pan-cancer companion diagnostic to match patients with rare genetic mutations for targeted therapy. This single test kit, which was recently launched across Europe, evaluates multiple tumor genes and biomarkers to reveal a patient's cancer's specific molecular profile.
•	In May 2022, Qlucore announced a new precision diagnostics collaboration to develop solutions for improved clinical diagnostics of bladder cancer. Qlucore's third classifier model collaboration in the area of solid tumors is for bladder cancer.


